Please assess the completion status of the following clinical trial:

Trial Title: Methylphenidate for Attention Deficit Hyperactivity Disorder and Autism in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~Autism/ADHD Group:~* DSM-IV diagnosis of autistic disorder, as per the Autism Diagnostic Interview-Revised (ADI-R) and the Autism Diagnostic Observation Schedule (ADOS)~* Child manifests current symptoms of ADHD~Autism/non-ADHD Group:~* Meets the diagnostic criteria for autism, as above, but does not meet the diagnostic criteria for ADHD~Exclusion Criteria:~In both groups, exclusion criteria will include:~* Sensory or motor deficits sufficient to interfere with testing (e.g., blindness, severe cerebral palsy)~* Serious neurological disorders (e.g., epilepsy, stroke)~* Down syndrome, fragile X syndrome, Tourette syndrome, or fetal alcohol syndrome~* Bipolar disorder or a family history of bipolar disorder in a first-degree relative~* Other serious psychopathology that resulted in psychiatric hospitalization (e.g., for psychotic episode). The investigators will screen for this using the Diagnostic Interview for Children and Adolescents (DICA)-IV, and getting a complete developmental/medical history~* Serious physical handicaps that would interfere with performance on laboratory tasks~* IQ less than 50 and greater than 130~* Verbal mental age (VMA) less than 36 months (to exclude participants unable to understand simple task instructions)~In the autism/ADHD group, further exclusion criteria apply to the MPH trial:~* History of intolerance to MPH~* Weight less than 20 kg or greater than 59 kg (less than 44 pounds or greater than 130 pounds)~* Concomitant use of dextroamphetamine preparations (Dexedrine, Dextrostat), mixed amphetamine salts (Adderall XR), other MPH preparations (e.g., Concerta, Metadate); venlafaxine, bupropion, atomoxetine, guanfacine, modafinil.~* Concomitant use of any herbal preparations~* Medical condition for which stimulants are contraindicated (e.g., high blood pressure)~* Past treatment failure on a methylphenidate trial

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 12 Years
- Healthy Volunteers: t

Study Arms:
- MPH Trial-Placebo (Type: PLACEBO_COMPARATOR): 24 Participants with ASD-ADHD underwent 1 week of placebo in the MPH treatment phase
- MPH Trial: Low Dose (Type: ACTIVE_COMPARATOR): 24 Participants with ASD-ADHD underwent 1 week at a low dose of Methylphenidate-extended release and Methylphenidate-immediate release in the MPH treatment phase
- MPH Trial: Med Dose (Type: ACTIVE_COMPARATOR): 24 Participants with ASD-ADHD underwent 1 week at a medium dose of Methylphenidate-extended release and Methylphenidate-immediate release in the MPH treatment phase
- MPH Trial: High Dose (Type: ACTIVE_COMPARATOR): 24 Participants with ASD-ADHD underwent 1 week at a high dose of Methylphenidate-extended release and Methylphenidate-immediate release in the MPH treatment phase

Based on this trial design, predict the completion outcome and termination type (if applicable).